Desvenlafaxine HCl | CAS#300827-87-6 | SERT/NET reuptake inhibitor

MedKoo Cat#: 527773 | Name: Desvenlafaxine HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Desvenlafaxine HCl is a dual SERT/NET reuptake inhibitor, being the major active metabolite of venlafaxine (GLXC-03750).

Chemical Structure

Desvenlafaxine HCl

CAS#300827-87-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 527773

Name: Desvenlafaxine HCl

CAS#: 300827-87-6 (HCl)

Chemical Formula: C16H26ClNO2

Exact Mass: 299.1652

Molecular Weight: 299.84

Elemental Analysis: C, 64.09; H, 8.74; Cl, 11.82; N, 4.67; O, 10.67

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
50mg	USD 650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

93413-62-8 (free base) 448904-47-0 (succinate) 386750-22-7 (succinate hydrate) 300827-87-6 (HCl) 93414-04-1 (fumarate) 1147940-37-1 (benzoate)

Synonym

Desvenlafaxine HCl; Desvenlafaxine hydrochloride;

IUPAC/Chemical Name

4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]-phenol hydrochloride

InChi Key

IMWPSXHIEURNKZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H25NO2.ClH/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1H

SMILES Code

OC1=CC=C(C(C2(O)CCCCC2)CN(C)C)C=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Desvenlafaxine (WY 45233 Succinate) is a serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor with Ki of 40.2 nM and 558.4 nM, respectively.

In vitro activity:

The purpose of this study was to characterize a new chemical entity, desvenlafaxine succinate (DVS). Competitive radioligand binding assays were performed using cells expressing either the human serotonin (5-HT) transporter (hSERT) or norepinephrine (NE) transporter (hNET) with K(i) values for DVS of 40.2 +/- 1.6 and 558.4 +/- 121.6 nM, respectively. DVS showed weak binding affinity (62% inhibition at 100 microM) at the human dopamine (DA) transporter. Inhibition of [3H]5-HT or [3H]NE uptake by DVS for the hSERT or hNET produced IC50 values of 47.3 +/- 19.4 and 531.3 +/- 113.0 nM, respectively. DVS (10 microM), examined at a large number of nontransporter targets, showed no significant activity. In conclusion, DVS is a new 5-HT and NE reuptake inhibitor in vitro that demonstrates good brain-to-plasma ratios, suggesting utility in a variety of central nervous system-related disorders. Reference: J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. https://pubmed.ncbi.nlm.nih.gov/16675639/

In vivo activity:

Desvenlafaxine (DVS) was orally administrated to UCMS mice at the dose of 10 mg/kg/day 1 week before they went through a 7-week stress procedure and lasted for over 8 weeks before the mice were killed. No significant changes were found for protein markers of neurons and astrocytes in UCMS mice. However, myelin and oligodendrocyte-related proteins were significantly reduced in UCMS mice. DVS prevented the stress-induced injury to white matter and the decrease of phosphorylated 5'-AMP-activated protein kinase and 3-hydroxy-3-methyl-glutaryl-CoA reductase protein expression. DVS increased open arm entries in an elevated plus-maze test, sucrose consumption in the sucrose preference test and decreased immobility in tail suspension and forced swimming tests. These findings suggest that stress induces depression-like behaviors and white matter deficits in UCMS mice. DVS may ameliorate the oligodendrocyte dysfunction by affecting cholesterol synthesis, alleviating the depression-like phenotypes in these mice Reference: J Neurochem. 2014 Oct;131(2):229-38. https://pubmed.ncbi.nlm.nih.gov/24934403/

Preparing Stock Solutions

The following data is based on the product molecular weight 299.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006 Aug;318(2):657-65. doi: 10.1124/jpet.106.103382. Epub 2006 May 4. PMID: 16675639. 2. Asokan A, Ball AR, Laird CD, Hermer L, Ormerod BK. Desvenlafaxine may accelerate neuronal maturation in the dentate gyri of adult male rats. PLoS One. 2014 Jun 4;9(6):e98530. doi: 10.1371/journal.pone.0098530. PMID: 24896246; PMCID: PMC4045676. 3. Wang J, Qiao J, Zhang Y, Wang H, Zhu S, Zhang H, Hartle K, Guo H, Guo W, He J, Kong J, Huang Q, Li XM. Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of the rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression. J Neurochem. 2014 Oct;131(2):229-38. doi: 10.1111/jnc.12792. Epub 2014 Jul 8. PMID: 24934403.

In vitro protocol:

In vivo protocol:

1. Asokan A, Ball AR, Laird CD, Hermer L, Ormerod BK. Desvenlafaxine may accelerate neuronal maturation in the dentate gyri of adult male rats. PLoS One. 2014 Jun 4;9(6):e98530. doi: 10.1371/journal.pone.0098530. PMID: 24896246; PMCID: PMC4045676. 2. Wang J, Qiao J, Zhang Y, Wang H, Zhu S, Zhang H, Hartle K, Guo H, Guo W, He J, Kong J, Huang Q, Li XM. Desvenlafaxine prevents white matter injury and improves the decreased phosphorylation of the rate-limiting enzyme of cholesterol synthesis in a chronic mouse model of depression. J Neurochem. 2014 Oct;131(2):229-38. doi: 10.1111/jnc.12792. Epub 2014 Jul 8. PMID: 24934403.

1: Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev. 2018 Feb 28;2:CD010292. doi: 10.1002/14651858.CD010292.pub2. Review. PubMed PMID: 29489029. 2: Hansen MR, Kuhlmann IB, Pottegård A, Damkier P. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships. Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):298-302. doi: 10.1111/bcpt.12796. Epub 2017 Jun 19. PubMed PMID: 28397349. 3: Alcantara-Montero A. [Desvenlafaxine and neuropathic pain: additional clinical benefits of a second generation serotonin-noradrenaline reuptake inhibitor]. Rev Neurol. 2017 Mar 1;64(5):219-226. Review. Spanish. PubMed PMID: 28229443. 4: Hellerstein DJ, Hunnicutt-Ferguson K, Stewart JW, McGrath PJ, Keller S, Peterson BS, Chen Y. Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study. J Affect Disord. 2017 Mar 1;210:258-264. doi: 10.1016/j.jad.2016.12.026. Epub 2016 Dec 20. PubMed PMID: 28064115. 5: Snyder MJ, Gibbs LM, Lindsay TJ. Treating Painful Diabetic Peripheral Neuropathy: An Update. Am Fam Physician. 2016 Aug 1;94(3):227-34. Review. PubMed PMID: 27479625. 6: Miranda LF, Domingues DS, Queiroz ME. Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2016 Aug 5;1458:46-53. doi: 10.1016/j.chroma.2016.06.024. Epub 2016 Jun 21. PubMed PMID: 27388659. 7: Xu Y, Bai SJ, Lan XH, Qin B, Huang T, Xie P. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability. Braz J Med Biol Res. 2016 May 24;49(6). pii: S0100-879X2016000600704. doi: 10.1590/1414-431X20164806. Review. PubMed PMID: 27240293; PubMed Central PMCID: PMC4897997. 8: Ghorbani M, Chamsaz M, Rounaghi GH. Glycine functionalized multiwall carbon nanotubes as a novel hollow fiber solid-phase microextraction sorbent for pre-concentration of venlafaxine and o-desmethylvenlafaxine in biological and water samples prior to determination by high-performance liquid chromatography. Anal Bioanal Chem. 2016 Jun;408(16):4247-56. doi: 10.1007/s00216-016-9518-8. Epub 2016 Apr 23. PubMed PMID: 27108286. 9: García-Galán MJ, Anfruns A, Gonzalez-Olmos R, Rodríguez-Mozaz S, Comas J. UV/H2O2degradation of the antidepressants venlafaxine and O-desmethylvenlafaxine: Elucidation of their transformation pathway and environmental fate. J Hazard Mater. 2016 Jul 5;311:70-80. doi: 10.1016/j.jhazmat.2016.02.070. Epub 2016 Mar 2. PubMed PMID: 26954478. 10: Serrano-Contreras JI, García-Pérez I, Meléndez-Camargo ME, Zepeda-Vallejo LG. NMR-based metabonomic analysis of normal rat urine and faeces in response to (±)-venlafaxine treatment. J Pharm Biomed Anal. 2016 May 10;123:82-92. doi: 10.1016/j.jpba.2016.01.044. Epub 2016 Feb 1. PubMed PMID: 26895493. 11: Hodgkin D, Horgan CM, Creedon TB, Merrick EL, Stewart MT. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans. J Ment Health Policy Econ. 2015 Dec;18(4):165-73. PubMed PMID: 26729008; PubMed Central PMCID: PMC4812668. 12: Staeheli SN, Gascho D, Fornaro J, Laberke P, Ebert LC, Martinez RM, Thali MJ, Kraemer T, Steuer AE. Development of CT-guided biopsy sampling for time-dependent postmortem redistribution investigations in blood and alternative matrices--proof of concept and application on two cases. Anal Bioanal Chem. 2016 Feb;408(4):1249-58. doi: 10.1007/s00216-015-9234-9. Epub 2015 Dec 16. PubMed PMID: 26677021. 13: Rejas Gutiérrez J, Blanca Tamayo M, Gascón Barrachina J, Armada Peláez B. [Economic evaluation of desvenlafaxine in the treatment of major depressive disorder in Spain]. Rev Psiquiatr Salud Ment. 2016 Apr-Jun;9(2):87-96. doi: 10.1016/j.rpsm.2015.08.002. Epub 2015 Oct 21. Spanish. PubMed PMID: 26475204. 14: Liu Y, Jann M, Vandenberg C, Eap CB, Shamsi SA. Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. J Chromatogr A. 2015 Nov 13;1420:119-28. doi: 10.1016/j.chroma.2015.09.088. Epub 2015 Oct 3. PubMed PMID: 26460073; PubMed Central PMCID: PMC5025041. 15: Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype. Ther Drug Monit. 2016 Feb;38(1):127-34. doi: 10.1097/FTD.0000000000000251. PubMed PMID: 26418700. 16: Zhan YY, Liang BQ, Wang H, Wang ZH, Weng QH, Dai DP, Cai JP, Hu GX. Effect of CYP2D6 variants on venlafaxine metabolism in vitro. Xenobiotica. 2016;46(5):424-9. doi: 10.3109/00498254.2015.1089364. Epub 2015 Sep 25. PubMed PMID: 26406933. 17: Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh MW, Hemmelgarn B, Dormuth CR, Ernst P; Canadian Network of Observational Drug Effect Studies (CNODES) Investigators. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1716-22. doi: 10.2215/CJN.11271114. Epub 2015 Jul 31. PubMed PMID: 26231193; PubMed Central PMCID: PMC4594079. 18: Zentner E, Weisbrod N, Gerstl Z, Gasser G, Ronen D. Puddles - A trigger for heterogeneous chemical influx into the unsaturated zone. Chemosphere. 2015 Sep;134:217-23. doi: 10.1016/j.chemosphere.2015.04.061. Epub 2015 May 15. PubMed PMID: 25957034. 19: Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, Ha JH, Shin HJ, Kim YH, Chung MW. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology (Berl). 2015 Jun;232(11):1899-909. doi: 10.1007/s00213-014-3825-6. Epub 2014 Dec 17. PubMed PMID: 25510856. 20: Magalhães P, Alves G, Rodrigues M, LLerena A, Falcão A. First MEPS/HPLC assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma. Bioanalysis. 2014;6(22):3025-38. doi: 10.4155/bio.14.222. PubMed PMID: 25496255.